| Acute exacerbation of COPD NA Dewan, S Rafique, B Kanwar, H Satpathy, K Ryschon, GS Tillotson, ... Chest 117 (3), 662-671, 2000 | 370 | 2000 |
| Comparative tolerability of the newer fluoroquinolone antibacterials P Ball, L Mandell, Y Niki, G Tillotson Drug safety 21, 407-421, 1999 | 341 | 1999 |
| Discovery research: the scientific challenge of finding new antibiotics DM Livermore, ... Journal of antimicrobial chemotherapy 66 (9), 1941-1944, 2011 | 338 | 2011 |
| Clostridium difficile infections among hospitalized children, United States, 1997–2006 MD Zilberberg, GS Tillotson, LC McDonald Emerging infectious diseases 16 (4), 604, 2010 | 303 | 2010 |
| Acute infective exacerbations of chronic bronchitis P Ball, JM Harris, D Lowson, G Tillotson, R Wilson QJM: An International Journal of Medicine 88 (1), 61-68, 1995 | 290 | 1995 |
| Tolerability of fluoroquinolone antibiotics: past, present and future P Ball, G Tillotson Drug safety 13 (6), 343-358, 1995 | 255 | 1995 |
| Quinolones: structure-activity relationships and future predictions GS Tillotson Journal of medical microbiology 44 (5), 320-324, 1996 | 239 | 1996 |
| Safety of fluoroquinolones: An update L Mandell, G Tillotson Canadian Journal of Infectious Diseases and Medical Microbiology 13, 54-61, 2002 | 166 | 2002 |
| The urgent need for new antibacterial agents R Wise, ... Journal of antimicrobial chemotherapy 66 (9), 1939-1940, 2011 | 152 | 2011 |
| Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid DJ Kuter, GS Tillotson Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (8 …, 2001 | 147 | 2001 |
| Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non … RJ Vickers, GS Tillotson, R Nathan, S Hazan, J Pullman, C Lucasti, ... The Lancet infectious diseases 17 (7), 735-744, 2017 | 140 | 2017 |
| Randomized controlled trial of a drug regimen that includes ciproftoxacin for the treatment of pulmonary tuberculosis N Kennedy, L Berger, J Curram, R Fox, J Gutmann, GM Kisyombe, ... Clinical infectious diseases 22 (5), 827-833, 1996 | 133 | 1996 |
| The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance P Peyrani, L Mandell, A Torres, GS Tillotson Expert review of respiratory medicine 13 (2), 139-152, 2019 | 126 | 2019 |
| Anti-infective research and development—problems, challenges, and solutions JS Bradley, R Guidos, S Baragona, JG Bartlett, E Rubinstein, GG Zhanel, ... The Lancet infectious diseases 7 (1), 68-78, 2007 | 123 | 2007 |
| Trojan horse antibiotics–a novel way to circumvent Gram-negative bacterial resistance? GS Tillotson Infectious Diseases: Research and Treatment 9, IDRT. S31567, 2016 | 121 | 2016 |
| The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia K Weiss, GS Tillotson Chest 128 (2), 940-946, 2005 | 112 | 2005 |
| National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 US Faropenem surveillance study IA Critchley, SD Brown, MM Traczewski, GS Tillotson, N Janjic Antimicrobial agents and chemotherapy 51 (12), 4382-4389, 2007 | 108 | 2007 |
| Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg bid versus … A Anzueto, MS Niederman, GS Tillotson, Bronchitis Study Group Clinical therapeutics 20 (5), 885-900, 1998 | 107 | 1998 |
| Clostridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March–April 2020 A Sandhu, G Tillotson, J Polistico, H Salimnia, M Cranis, J Moshos, ... Emerging Infectious Diseases 26 (9), 2272, 2020 | 103 | 2020 |
| Evaluation of the clinical microbiology profile of moxifloxacin C Krasemann, J Meyer, G Tillotson Clinical Infectious Diseases 32 (Supplement_1), S51-S63, 2001 | 103 | 2001 |
